Aesica is a leading pharmaceutical CDMO serving pharmaceutical companies with active pharmaceutical ingredient (API) and finished dose formulation development and manufacturing services.
Aesica’s business model has, historically, been built on four key pillars:
- Strategic partners
- Organic growth
Aesica considers strategic partners to be those where there is potential to create significant revenues across the Aesica network. As the industry is shifting towards supply chain consolidation, Aesica focuses on the retention and formation of strong partnerships with global pharmaceutical companies, generics companies and regional players through new business development and key account management.
Aesica’s goal is to broaden its technology offering through both acquisition and innovation and, in 2012, the Aesica Innovation Board was established to identify and commercialise technologies. Aesica’s intention is to continue to achieve organic growth by building on Aesica’s foundations of new business development, key account management, project management and continuous improvement.